What is the current Price Target for the Actuate Therapeutics stock?

The average Actuate Therapeutics target price is $12.24. This is 1,394.51% higher than the current stock price. The highest price target is 1,823.08%, the lowest is 886.57%. 5 Analysts have issued a price target Actuate Therapeutics 2027 .

How high will the Actuate Therapeutics stock rise?

No reliable answer can be given as to how high the Actuate Therapeutics stock will rise. The performance of stocks, including the Actuate Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Actuate Therapeutics stock today?

The performance of Actuate Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Actuate Therapeutics stock fall?

The decline in Actuate Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Actuate Therapeutics Forecast, price target & analysts

$0.82

7.89%

Nasdaq, Oct 02, 04:00 pm EDT. Closed.

ISIN

US0050831009

Symbol

ACTU

Reports

Quarter | Annual

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Analysts Charts Ownership News Strategies

Actuate Therapeutics Target price 2026 - Analyst rating & recommendation

Actuate Therapeutics Classifications & Recommendation

Buy

89%

Hold

11%

Actuate Therapeutics Price Target

Target Price	$12.24
Price	$0.82
Potential	1,394.51% register free of charge
Number of Estimates	5

	5 Analysts have issued a price target Actuate Therapeutics 2027 . The average Actuate Therapeutics target price is $12.24. This is 1,394.51% register free of charge higher than the current stock price. The highest price target is $15.75 1,823.08% register free of charge , the lowest is $8.08 886.57% register free of charge .
	A rating was issued by 9 analysts: 8 Analysts recommend Actuate Therapeutics to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Actuate Therapeutics stock has an average upside potential 2027 of 1,394.51% register free of charge . Most analysts recommend the Actuate Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '25	2026 Estimates
Earnings Per Share $	-1.06	-0.74
	24.29%	30.19%
P/E		negative

5 Analysts have issued a Actuate Therapeutics forecast for earnings per share. The average Actuate Therapeutics EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$-1.06	24.29%
2026	$-0.74 30.19% unlock
2027	$-0.68 8.11% unlock
2028	$-0.70 2.94% unlock
2029	$-0.66 5.71% unlock
2030	$-0.16 75.76% unlock
2031	$2.38 1,587.50% unlock
2032	$2.84 19.33% unlock
2033	$3.29 15.85% unlock

Current	-0.96	82.52%
2026	-1.10 14.17% unlock
2027	-1.21 10.00% unlock
2028	-1.16 4.13% unlock
2029	-1.25 7.76% unlock
2030	-5.18 314.40% unlock
2031	0.34 106.56% unlock
2032	0.29 14.71% unlock
2033	0.25 13.79% unlock

Actuate Therapeutics...

Current Actuate Therapeutics Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Aug 18 2026
Rodman & Renshaw	Locked ➜ Locked	Locked	Jul 30 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	May 18 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Apr 22 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Apr 13 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 19 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 23 2025

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Aug 18 2026
Locked Rodman & Renshaw: Locked ➜ Locked	Jul 30 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	May 18 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Apr 22 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Apr 13 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 19 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 23 2025

Discover more stocks with a high price target

NIO ADR 86.90%

Alibaba Group Holding Ltd 81.89%

Rheinmetall 70.55%

Tencent Holdings Ltd. 61.28%

Adyen 56.67%

Uber Technologies 51.26%

BYD 50.30%

Siemens Energy 43.79%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now